CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30 – 11:30 am EDT at the Harvard Club in New York City. The event, which will be open to analysts and institutional investors, will include presentations by, and a panel discussion with, key opinion leaders in oncology and sarcoma, including the principal investigator for the Company’s pivotal, global Phase 3 trial of aldoxorubicin in patients with soft tissue sarcoma. Breakfast will be served. Please RSVP to firstname.lastname@example.org. CytRx invites the public and the media to join the event via the webcast. Speakers scheduled to present include: Daniel Von Hoff, M.D., F.A.C.P. Dr. Von Hoff currently serves as Physician in Chief and Director of the Translational Genomics Research Institute (TGEN) in Phoenix, Arizona. He is also Chief Scientific Officer for the US Oncology Network, one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. He is currently serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee. Dr. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and is currently editor-in-chief of Molecular Cancer Therapeutics. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla is the Principal Investigator for the aldoxorubicin global Phase 3 pivotal trial in second-line soft tissue sarcoma. He was the Principal Investigator for the Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin. Dr. Chawla currently serves as Director of Medical Oncology at the UCLA-Santa Monica Hospital, Director of Medical Oncology at Orthopaedic Hospital, and as Director of Medical Oncology at Century City Hospital. Dr. Chawla also currently heads the Sarcoma Oncology Center in Santa Monica, CA. Following completion of his medical degree and residency training at the All India Institute of Medical Sciences in New Delhi, Dr. Chawla completed a fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.), and later, in recognition for his outstanding academic accomplishments, he was invited to continue his fellowship in oncology at the prestigious M.D. Anderson Cancer Center of the University of Texas.
Om Prakash, Ph.D.Dr. Prakash and his research group at Louisiana State University are responsible for the evaluation of aldoxorubicin in animal models of glioblastoma. He currently serves as Research Professor of Medicine at the Stanley S. Scott Cancer Center at the Louisiana State University Health Sciences Center, Department of Microbiology, Immunology and Parasitology. Prior to that, he served as Head of the Laboratory of Molecular Oncology and as an instructor at Cornell University’s Graduate School of Medical Sciences. Dr. Prakash also served as a senior staff associate at the Sloan-Kettering Institute for Cancer Research and at the College of Physicians and Surgeons of Columbia University. Daniel Levitt, M.D., Ph.D. Dr. Levitt currently serves as Executive Vice President and Chief Medical Officer at CytRx Corporation. Prior to joining CytRx, Dr. Levitt served as Executive Vice President, Research and Development at Cerimon Pharmaceuticals, Inc. Prior to that he served in executive and senior management roles at multiple world-renowned life science companies including Dynavax Technologies Corporation, Affymax, Inc., Protein Design Labs, Inc., Geron Corporation, Sandoz Pharmaceuticals Ltd., and Hoffmann-LaRoche, Inc. Dr. Levitt has received 10 major research awards and authored or co-authored approximately 200 papers and abstracts. Felix Kratz, Ph.D. Dr. Kratz is the inventor of aldoxorubicin and currently serves as Vice President of Drug Discovery at CytRx Corporation. Prior to joining CytRx, Dr. Kratz was the Head of the Division Macromolecular Prodrugs, which he founded in 1994, in the Clinical Research Department at the Tumor Biology Center (KTB Tumorforschungs GmbH) in Freiburg, Germany. Dr. Kratz serves on the Editorial Board for Bioconjugate Chemistry, Current Medicinal Chemistry, Current Bioactive Compounds, and Pharmacology & Pharmacy. He has authored approximately 260 scientific publications and proceedings and is the inventor of 23 patents and patent applications. Date: Friday, May 2, 2014 Time: 8:30 am – 11:30 am Location: The Harvard Club, 35 West 44 th Street, New York, NY RSVP: email@example.com A webcast of the presentation can be accessed at the following link: http://wsw.com/webcast/cc/cytr/register.aspx?conf=cc&page=cytr&url=http%3A//wsw.com/webcast/cc/cytr/ A replay of the webcast will also be archived on the Investor Relations section of the CytRx website following the event.
About CytRx CorporationCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx has initiated under a special protocol assessment a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and recently announced that it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. CytRx has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer), and a Phase 2 clinical trial in HIV-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical trials, the risk that any future human testing of aldoxorubicin, might not produce results similar to those seen in past human or animal testing, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.